
Immunome (IMNM) Stock Forecast & Price Target
Immunome (IMNM) Analyst Ratings
Bulls say
Immunome is supported by a pipeline that is already generating de-risking clinical and regulatory evidence, led by varegacestat’s Phase 3 RINGSIDE results showing an 84% reduction in progression or death, a 55.7% ORR versus 9.1% on placebo, and durable pain and function improvements that strengthen the approval case ahead of the April 28, 2027 PDUFA. Its ROR1 ADC IM-1021 also showed encouraging early activity, with a 53% ORR and 26% CR rate across efficacy-evaluable patients, including 64% ORR in DLBCL, while IM-1340 has IND clearance and IM-1335 remains on track for YE26 submission. Beyond the lead assets, the company’s broader oncology platform and HC74 TOP1i payload strategy support multiple shots on goal, even as higher operating expense is pressuring valuation in the near term.
Bears say
Immunome is burdened by a lead asset, varegacestat, that appears to enter a desmoid tumors market already mapped by Ogsiveo over three years earlier, making differentiation on efficacy, pain, and convenience difficult and exposing the launch to incumbent and next-class risk. Although the model implies 3Q26-ending cash of $461.6mm and runway into 2028, the added $20mm cash payment, 4.4mm shares issued in 4Q26, and rising operating expenses increase dilution and execution pressure. The ADC and radioligand pipeline remains more speculative, with IM-1021 still in Phase 1, IM-3050 requiring funding alongside launch, and preclinical programs lacking the readouts needed to offset the weaker near-term commercial and regulatory profile.
This aggregate rating is based on analysts' research of Immunome and is not a guaranteed prediction by Public.com or investment advice.
Immunome (IMNM) Analyst Forecast & Price Prediction
Start investing in Immunome (IMNM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Immunome (IMNM) Forecast
Immunome (IMNM) Analyst Forecast & Price Prediction
Start investing in Immunome (IMNM)
Order type
Buy in
Order amount
Est. shares
0 shares